The association of tamoxifen (an effective hormone therapy used to treat hormone receptor-positive breast cancer) use with the risk of endometrial cancer in premenopausal women with breast cancer remains controversial. In a recently published study, the association of tamoxifen use and the risk of endometrial cancer and other uterine diseases in premenopausal women with breast cancer was evaluated.
Findings suggest that clinicians should consider the risk of uterine disease among tamoxifen users, including premenopausal women.
Participants included premenopausal Korean women aged 20 to 50 years with breast cancer diagnoses between January 2003 and December 2018. The incidence of uterine diseases, including endometrial cancer, hyperplasia (enlargement of tissue due to increased cellular reproduction), polyps (benign growths), and other uterine cancers, was identified in the study. Among 78,320 female participants, 34,637 (44.2%) were categorized into the tamoxifen group and 43,683 (55.8%) were categorized into the control group. Among tamoxifen users, the risk of endometrial cancer was higher than in the control group. In this study, premenopausal Korean women with breast cancer who received tamoxifen as adjuvant hormone therapy had a significantly increased risk of endometrial carcinoma and other uterine cancers compared with those who were not treated with tamoxifen. These findings suggest that clinicians should consider the risk of uterine disease among tamoxifen users, including premenopausal
women.
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media: